Ecolab Life Sciences has opened a new bioprocessing applications laboratory in King of Prussia, Pennsylvania, aiming to provide end-to-end support for the development and purification of biotherapeutic molecules.

The new site is designed to assist biopharma companies and contract manufacturers with process development across the entire product lifecycle—from early-stage development through to commercial manufacturing.

Equipped with high-throughput screening tools and manufacturing-scale chromatography columns, the company says the facility will support activities such as resin screening, regulatory data generation, and process optimization.

The opening marks a focused investment in Ecolab’s US capabilities, placing the new lab in close proximity to one of the country’s most active pharmaceutical and biotech regions. King of Prussia, located near Philadelphia, is home to several large pharmaceutical operations and a growing cluster of bioprocessing innovation.

“Biopharma companies increasingly need technical partners who can support them with both scientific depth and operational agility,” said Jennifer Sorrells, Ph.D., vice president of research and development at Ecolab Life Sciences.

“This facility demonstrates our commitment to optimizing purification workflows and accelerating the delivery of life-saving therapies to patients.”

In addition to offering analytical and technical support, the site is already being used by biopharmaceutical and contract manufacturing organizations to conduct lifecycle studies aimed at improving manufacturing efficiency and reducing time to market.

According to the company, the lab can initiate and complete studies within a matter of weeks, providing raw data access and bench-level collaboration throughout.

The new lab complements Ecolab’s existing European R&D site in Wales and forms part of the company’s broader Pharma Center of Excellence initiative. The multi-million dollar program also includes a customer experience center—The Xchange—and facilities for the production of active pharmaceutical ingredients (APIs) and excipients.

As downstream purification continues to be a bottleneck in biologics manufacturing, the industry has seen growing demand for application labs that can support rapid iteration and scale-up. This latest investment underscores a broader trend of biopharma suppliers building localized capabilities to serve regional customers more efficiently.